Showing results (141-150 of 214) with videos related to

Sort By:
Pageof 22
Leukemia Research|March 15, 2001
Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL)A Aguayo, T Manshouri, S O'Brien, et al.
Leukemia|January 1, 1987
Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferonM Beran, B Andersson, H Kantarjian, et al.
Cancer|August 15, 1986
The association of specific "favorable" cytogenetic abnormalities with secondary leukemiaH M Kantarjian, M J Keating, R S Walters, et al.
Blood|September 15, 1993
Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatmentS O'Brien, H Kantarjian, M Beran, et al.
ORL; Journal for Oto-Rhino-Laryngology and Its Related Specialties|January 1, 1977
Preoperative facial paralysis in malignant parotid tumoursC M Eneroth, L Andreasson, M Beran, et al.
Cancer|October 1, 1993
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemiaS Suki, H Kantarjian, V Gandhi, et al.
Haematology and Blood Transfusion|January 1, 1990
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSFE H Estey, H M Kantarjian, M Beran, et al.
Cancer|January 28, 1999
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literatureA Aguayo, J E Cortes, H M Kantarjian, et al.
Cancer Research|August 1, 1993
Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phaseM Beran, P Pisa, S O'Brien, et al.
British Journal of Haematology|September 1, 1994
Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimenH M Kantarjian, S O'Brien, T Smith, et al.
Pageof 22